BOSTON--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical analysis, today reported financial results for the quarter and full year ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Investors might want to bet on 908 Devices Inc. (MASS), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- ...
“We entered 2026 from a position of strength with a streamlined cost structure, a solid balance sheet and an expanding recurring revenue opportunity,” said (Co-Founder, CEO, President & Director Kevin ...
The average one-year price target for 908 Devices (NasdaqGM:MASS) has been revised to $11.22 / share. This is an increase of 10.00% from the prior estimate of $10.20 dated April 25, 2026. The price ...
908 Devices is revolutionizing chemical analysis with its simple handheld devices for vital health, safety and defense tech applications, addressing the fentanyl and illicit drug crisis, toxic ...
On Tuesday, Repligen Corporation (NASDAQ:RGEN) purchased 908 Devices Inc.’s (NASDAQ:MASS) desktop portfolio of four devices for bioprocessing process analytical technology (PAT) applications. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results